Clinical Trial

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in patients with ROS1-fusion positive stage IB, II, IIIA NSCLC. The study will evaluate if taletrectinib is better than placebo at preventing the participant's disease from coming back after the participant's lung tumor was removed.
Protocol Amendment History 2 changes
notable Trial sites expanded: 29 -> 33 locations 2026-05-20
notable Trial sites expanded: 12 -> 29 locations 2026-04-09
Trial Details
NCT Number NCT07154706
Lead Sponsor Nuvation Bio Inc.
Conditions Non-small Cell Lung Cancer (NSCLC)
Enrollment 180 participants
Start Date 2025-08-21
Primary Completion 2030-08-30 (estimated)
Study Completion 2033-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-19